CXCR4 and acute myeloid leukemia: These findings indicate that the dual blockade of CXCR4 and PD-1, alongside chemotherapy, could significantly improve outcomes for PDAC patients.440 Besides, in a phase IIa clinical trial, the safety and effectiveness of combining BL-8040 with high-dose cytarabine (HiDAC) were assessed in patients with relapsed and refractory acute myelogenous leukemia (AML).441 The study explored six escalating doses of BL-8040, ultimately selecting 1.5 mg/kg for an extended evaluation based on safety and tolerability across all levels.